Streetbeat News

Products Services

BLNK

Blink Charging Co (NASDAQ:BLNK) plans to incorporate the North America Charging Standard (NACS) and Combined Charging System (CCS) into its charging products line. The company will start producing NACS DCFC chargers by October 2023 and will also include NACS in its Level 2 chargers, which account for about 90% of EV charging use in the U.S. The company's shares are trading higher by 2.9% at $5.51.

Portfolio Pulse from Shivani Kumaresan

June 28, 2023 | 3:45 pm

FHTX

Foghorn Therapeutics has announced data from a Phase 1 study of FHD-286 in metastatic uveal melanoma, validating its safety and tolerability. However, the company will not pursue FHD-286 for this condition. Instead, Foghorn plans to initiate a Phase 1 study of FHD-286 in combination with decitabine or cytarabine for relapsed and/or refractory AML patients. Earlier this month, the FDA lifted the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in acute myelogenous leukemia and myelodysplastic syndrome.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 3:44 pm

WDAY

Workday Inc (NASDAQ:WDAY) has been identified by RBC Capital Markets analyst Rishi Jaluria as having a 'long runway of growth' with more than 20% subscription growth expected. The company's expansion from core HR into financials, coupled with a successful evolution into a multi-product platform, is likely to drive this growth. Jaluria initiated coverage of Workday with an Outperform rating and a price target of $275.

Portfolio Pulse from Priya Nigam

June 28, 2023 | 3:42 pm

WBD

Warner Bros. Discovery Inc. plans to add live programming from CNN to its Max streaming service later this year. The move is aimed at attracting more subscribers. Live news will also be added to the service outside the US.

Portfolio Pulse from Happy Mohamed

June 28, 2023 | 3:42 pm

CGTX

Cognition Therapeutics Inc (NASDAQ:CGTX) announced the results from its Phase 2 study of CT1812 in adults with Alzheimer's disease. The study met its primary endpoints for safety and tolerability, and demonstrated positive effects for CT1812-treated participants. However, the results were not statistically significant, which may be causing investor concern. CGTX shares are down 20.0% at $2.00.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 3:40 pm

ZI

Shares of ZoomInfo Technologies Inc (NASDAQ:ZI) climbed after the company released new product features based on Generative AI. Needham analyst Joshua Reilly initiated coverage of ZoomInfo with a Buy rating and a price target of $35, citing the company's potential for accelerated growth and attractive unit economics. The stock's current valuation offers an attractive entry point, especially for those who can wait for a recovery in demand for the company's solutions.

Portfolio Pulse from Priya Nigam

June 28, 2023 | 3:35 pm

AMZN

Amazon's cloud subsidiary, AWS, has launched AppFabric, a no-code service that integrates SaaS apps. The product is expected to reduce customer churn by increasing exit costs. AWS plans to launch an AI assistant by the end of the year, which will be able to convert email threads or Slack conversations into an Asana task list. Needham analyst Laura Martin maintains a Buy rating on Amazon, raising the price target from $120 to $150.

Portfolio Pulse from Anusuya Lahiri

June 28, 2023 | 3:34 pm

BABA

MA

TCEHY

V

Tencent Holding Ltd (TCEHY) and Alibaba Group Holding Limited (BABA) fintech affiliate Ant Group have extended support for linking international credit cards to their platforms, WeChat and Alipay respectively. This move is aimed at providing greater convenience for foreign tourists and expanding the usage of WeChat Pay and Alipay in China's market. Visa Inc (V) and Mastercard Inc (MA) are the credit card companies involved in this initiative.

Portfolio Pulse from Anusuya Lahiri

June 28, 2023 | 3:29 pm

ALZN

Alzamend Neuro's CEO, Stephan Jackman, has projected that the company will see topline results from its combined Phase I & Phase II vaccine by 2024.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 3:14 pm

ALZN

Alzamend Neuro's CEO, Stephan Jackman, has announced that the company plans to submit three Investigational New Drug applications (INDs) to the FDA in 2023. These applications will be for treatments of bipolar disorder, major depressive disorder, and PTSD.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 3:13 pm